Research  >  Research  >  Scientist Profiles

Scientist profiles A-F

SRI profiles

Kelvin Chan
Kelvin Kar-Wing Chan, MD, FRCPC, M.Sc., PhD

Medical Oncologist
Associate scientist

Odette Cancer Centre
Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room T2-058
Toronto, ON
M4N 3M5

Phone: 416-480-4928
Fax: 416-480-6002


  • B.Sc., 1995, human biology, University of Toronto, Canada
  • MD, 1999, U of T, Canada
  • M.Sc., 2007, health administration (clinical epidemiology), U of T, Canada
  • M.Sc., 2010, biostatistics, U of T, Canada
  • PhD, 2017, biostatistics, U of T, Canada

Appointments and Affiliations:

  • Associate scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute
  • Professor, department of medicine, U of T
  • Staff medical oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre
  • Co-director, Canadian Centre for Applied Research in Cancer Control 
  • Clinical lead, provincial drug reimbursement programs, Cancer Care Ontario

Research Foci:

  • Medical oncology
  • Head & neck malignancies
  • Clinical epidemiology
  • Health economics
  • Cost-effectiveness analysis
  • GI malignancies
  • Decision analysis
  • Biostatistics

Selected Publications:

See current publications list at PubMed

  1. Chan KKW, Shah K, Lien K, Coyle D, Lam H, Ko Y. A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. PLoS One. 2014 Oct 6;9(10):e108749.
  2. Chan KK, Willan AR, Gupta M, Pullenayegum E. Underestimation of uncertainties in health utilities dervied from mapping algorithms involving health-related quality-of-life measures: statistical explanations and potential remedies. Med Decis Making. 2014 Oct;34(7):863–72.
  3. Chan KK, Siu E, Cheung MC, Mozessohn L. Publication patterns of cancer cost-effectiveness studies presented at major conferences. Curr Oncol. 2013 Dec;20(6):319–25.
  4. Chan KK, Wong B, Siu LL, Straus SE, Chang J, Berry SR. Less than ideal: how oncologists practice with limited drug access. J of Oncol Pract. 2012 May;8(3):190–5.
  5. Chan KK, Siu E, Krahn M, Imrie K, Alibhai S. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. J of Clin Oncol. 2012 Apr 1;30(10):1064–71.

Related News and Stories: